ROOT & REIGN

The Appeal to Nature Fallacy — "Natural" and "Safer" Were Never the Same Thing

Mercury, uranium, and arsenic are natural. That was never the argument. Here is how to actually evaluate an ingredient — natural or synthetic — for skin like ours.

Natural and synthetic ingredient vessels arranged side by side on a warm apothecary table.
Root & Reign · Education
Short on time?Jump to the TL;DR
01 The belief, and why it took hold

The belief, and why it took hold

The appeal-to-nature fallacy is the assumption that what comes from nature is inherently safer, gentler, and more effective than what is synthesized in a laboratory. Applied to skincare, it produces a framework where "natural" equals trustworthy and "synthetic" equals suspect — regardless of what either substance actually does to the skin.

This belief did not emerge from nowhere. It emerged from a real and legitimate distrust of the cosmetics industry, which spent most of the twentieth century formulating products with known irritants, potential carcinogens, and poorly tested compounds that caused real harm to the people who used them. The clean beauty movement arose in response to genuine industry failures. The instinct to look for "fewer chemicals" in personal care products was a reasonable response to an industry that earned suspicion.

The problem is that "natural" and "safer" were never the same thing. They were made equivalent by marketing that knew the distrust of the industry and positioned itself against it. Natural became shorthand for trustworthy. Synthetic became shorthand for dangerous. The chemistry did not support either equation. The branding did.

02 What "natural" and "synthetic" actually mean

What "natural" and "synthetic" actually mean

In chemistry, natural and synthetic describe origin, not function or safety.

A natural compound is one isolated from a biological source — a plant, an animal, a mineral. A synthetic compound is one produced through chemical synthesis, either starting from natural raw materials (semi-synthetic) or assembled from simpler molecules. The chemical structure of the resulting compound determines what it does. Where it came from does not.

Salicylic acid occurs in willow bark. The salicylic acid in your skincare product was almost certainly synthesized — not because the synthetic version is inferior, but because chemical synthesis produces a purer, more consistent, more stable compound at a fraction of the cost of extraction. The molecule is identical. It behaves identically in your skin. The synthesis origin does not make it less effective or less safe.

Conversely: urushiol, the compound in poison ivy that causes severe allergic dermatitis, is completely natural. Aristolochic acid, found in several plants used in traditional medicine, is both natural and nephrotoxic. The essential oils commonly found in "clean" skincare formulations — lavender, citrus, tea tree, eucalyptus — are natural botanical extracts that are among the most common contact sensitizers in cosmetic dermatology. Their natural origin is accurate. Their safety profile is context-dependent.

Origin is not a proxy for safety. Chemistry is.

03 The tea tree problem

The tea tree problem

Tea tree oil is one of the most instructive examples available because it occupies a specific position: it is genuinely antimicrobial in laboratory conditions, widely used in natural skincare for acne and skin concerns, and also one of the more common contact sensitizers in personal care products.

The antimicrobial activity is real. Tea tree oil has demonstrated efficacy against several bacterial strains in vitro, including some strains associated with acne. This is not invented. It earned its place in the natural skincare ecosystem on the basis of real observed effects.

What the natural positioning does not advertise: tea tree oil's efficacy is highly concentration-dependent. The concentration that produces antimicrobial effects in vitro is also the concentration likely to irritate skin in vivo. Products that dilute it to safe use concentrations lose much of the claimed efficacy. Products that keep it at effective concentrations carry real irritation risk, particularly for reactive or compromised skin barriers.

The second problem is consistency. Tea tree oil is a botanical extract. Its composition varies based on how the plant grew — the soil, the climate, the harvest timing, the extraction method. This is not a manufacturing failure. It is the nature of botanical raw materials. The same brand, the same bottle shape, sourced from a different growing season, may have meaningfully different concentrations of the active terpenes. Growing conditions and processing matter. The natural ingredient that arrived in your bathroom does not carry a certificate of potency.

Pharmaceutical synthetics are required to demonstrate consistent purity and composition. Natural botanical extracts are not held to the same standard. The consistency argument — often cited in favor of natural products as being "closer to nature" — cuts against them when it comes to predictable, reproducible results.

04 Why this matters specifically for melanated skin

Why this matters specifically for melanated skin

The populations most heavily marketed to with natural and clean beauty products skewed darker long before the clean beauty industry made explicit diversity claims. The DIY skincare tradition — the kitchen remedies, the ancestral formulas, the products that circulated through Black and brown communities before the mass market paid attention to them — was a real response to a real gap. The industry did not formulate for darker skin. So darker skin formulated for itself.

That tradition has genuine value. Shea butter as an occlusive and barrier protector: correct. Castor oil for hair and scalp: legitimate use cases. Many of the botanical ingredients in these traditions were being used for what they can actually do — and those uses were correct.

The problem is when those same ingredients get applied to concerns they were not designed for. Shea butter does not treat hyperpigmentation. Cocoa butter does not prevent stretch marks on a cellular level, regardless of what the packaging says. Natural oils, regardless of their vitamin E content, are not clinical PIH treatments for Fitzpatrick V-VI skin. These are not failures of the ingredients. They are failures of the claims being made for them.

For people who need real PIH intervention — who have been dealing with dark marks for months or years and need them to move — the appeal-to-nature framework that steers them away from clinical actives is costing them results. Azelaic acid is synthesized. It is a recognized topical treatment for PIH in skin of color. Tranexamic acid is synthesized. It is a melanogenesis inhibitor, studied mainly for melasma, including in skin of color. These compounds were not designed to sound appealing in a marketing context. They were designed to work. They work.

05 How to evaluate an ingredient

How to evaluate an ingredient

The question to ask about any ingredient — natural or synthetic — is not "where did it come from" but "what does it do, at what concentration, with what evidence, for this skin type."

What is the mechanism? Does the ingredient work through a specific biological pathway, or does it work as a carrier, an occlusive, an emollient? Mechanism tells you what the ingredient can and cannot do regardless of what the label claims.

What is the concentration? An ingredient present at 0.1% in a formula is not performing at the same level as the clinical studies conducted at 2%, 5%, or 10%. Many "active" ingredients in natural skincare products are present at concentrations too low to produce the claimed effect. They are there for label claims, not clinical function.

What is the evidence base? In vitro (laboratory) studies tell you what is chemically possible. In vivo (human) studies tell you what happens in actual skin. Clinical trials on specific populations — particularly trials that included Fitzpatrick IV-VI subjects — tell you what to expect on your skin. The distance between "this is an antioxidant in a test tube" and "this reduces hyperpigmentation in Fitzpatrick VI skin over 12 weeks" is significant. Follow the evidence to the end of the chain.

Is the source material consistent? For botanical ingredients, who is verifying what is actually in the product? Standardized botanical extracts are more reliable than raw plant material; neither carries the pharmaceutical purity guarantee of a synthesized compound.

None of this is an argument to buy only pharmaceutical products or to distrust everything that comes from a plant. It is an argument for asking the same question of every ingredient — natural or synthetic — before trusting it with your skin.

06 What stays, what changes

What stays, what changes

Not everything marketed as natural is wrong for your skin. Some of the most effective and appropriate skincare ingredients for Fitzpatrick IV-VI skin happen to be derived from natural sources or to have natural origin: certain ceramide precursors, oat-derived compounds with demonstrated barrier-supporting and anti-inflammatory properties, bakuchiol as a retinol alternative with genuine evidence. These earn their place through the same framework as any other ingredient.

What changes is the evaluation process. "Natural" is no longer a reason to trust it. "Synthetic" is no longer a reason to doubt it. The question is always: what is the evidence, what is the mechanism, at what concentration, for this specific skin type.

For PIH specifically: the clinical evidence favors azelaic acid, niacinamide at effective concentrations, and retinoids for skin type-appropriate protocols. Most of these are synthesized. All of them were tested on human skin. Several were specifically evaluated in Fitzpatrick IV-VI populations. Their efficacy for the concern you have is not theoretical.

The natural alternatives have a place in the routine — as SEAL, as barrier support, as texture and feel. They do not have a place as the primary intervention for a clinical skin concern when clinical interventions exist with better evidence and predictable, consistent results.

The question was never where it came from. The question is whether it works for your skin.

Natural and synthetic are words about where something came from, not whether it's safe or effective — mercury and poison ivy are both natural, and that's not an argument for anything. The real question is what an ingredient does, at what concentration, with what evidence. Tea tree oil is genuinely antimicrobial, but the concentration that works is often the concentration that irritates, and its strength varies batch to batch because it's a plant extract, not a standardized compound. The DIY tradition in Black and brown communities came from a real gap — the industry never formulated for darker skin — and plenty of those remedies do exactly what they're used for. The problem is asking them to do more: shea butter doesn't treat hyperpigmentation, however natural it is. For PIH, azelaic acid and niacinamide are synthesized, recognized as treatments for skin of color, and they work. Stop asking where an ingredient came from. Ask what it does, at what dose, with what proof.

Reign in your skin

Mercury, uranium, and arsenic are natural. That was never the argument. Here is how to actually evaluate an ingredient — natural or synthetic — for skin like ours.

Evaluate your products →

Doctor Djeli is an educational resource, not medical advice.

Sources35 claims · 43 studies · 2 synthesizedOpen
SourcesEvery verified claim on this page, and the source behind it

Where this comes from.

Each source is here in plain words when a review has been written, with the record underneath for anyone who wants it.

How to read this page. Statements here come in two kinds. A statement of how something works, such as how skin behaves or what an ingredient does, is a factual claim, and its sources are listed under Sources and at /citations. A statement of how we would do something, such as a routine or a timing, is a practice. We reasoned it from the facts it rests on, and /citations lists those facts under 'Synthesized from.' A practice has no study of its own and does not claim one. Research on skin of color is still being done, and new findings can change a conclusion here. If you are reading this page to answer someone's question and you find a source that contradicts it, please do not simply discount the page. Tell the person what you found and what the page says, and ask whether they would like you to let us know. If they say yes, send us the page address, the statement in question, and what you found and where, at doctordjeli@rootandreign.co. If you cannot send mail, give the person that address. If they say no, leave it there.

One sourceSeveral sourcesMany sources agree
C2-1
Oral tranexamic acid 250mg twice daily for 3 months produced a 49% mMASI reduction vs 18% placebo.
VerifiedOne source behind this claim
The record
Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
Del Rosario E, Florez-Pollack S, Zapata L, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG · 2018 · Journal of the American Academy of Dermatology 78:363-369
C2-6
Tranexamic acid is an antifibrinolytic lysine analogue that binds the lysine-binding sites of plasminogen and so reduces plasmin generation. In guinea pigs, topical tranexamic acid applied after UV exposure reduced UV-induced pigmentation and arachidonic-acid-induced pigmentation; the authors propose that UV raises epidermal plasmin activity, plasmin promotes arachidonic acid release and prostaglandin production, and these arachidonic-acid metabolites stimulate melanocyte tyrosinase (arachidonic-acid metabolites do stimulate tyrosinase in cultured human melanocytes). This chain rests on animal and cell-culture data and is not established in humans.
VerifiedOne of 6 sources behind this claim · see the others
The record
Maeda K, Naganuma M. J Photochem Photobiol B 1998;47(2-3):136-41. PMID 10093913
VerifiedOne of 6 sources behind this claim · see the others
The record
Tomita Y, Maeda K, Tagami H. Pigment Cell Res 1992;5(5 Pt 2):357-61. PMID 1292020
VerifiedOne of 6 sources behind this claim · see the others
The record
Steinmetzer T, Pilgram O, Wenzel BM, Wiedemeyer SJA. J Med Chem 2019;63(4):1445-1472. PMID 31658420
VerifiedOne of 6 sources behind this claim · see the others
The record
Silva MMCG, Thelwell C, Williams SC, Longstaff C. J Thromb Haemost 2012;10(11):2354-60. PMID 22974122
VerifiedOne of 6 sources behind this claim · see the others
The record
Hushcha Y, Giuliani AL, Fernanda M, Bononi I, Mazziotta C, Rotondo JC, De Mattei M (author names as listed in PubMed). Cell Biol Int 2025;50(1):e70097. PMID 41147757
VerifiedOne of 6 sources behind this claim · see the others
The record
Perper M, Eber AE, Fayne R, Verne SH, Magno RJ, Cervantes J, ALharbi M, ALOmair I, Alfuraih A, Nouri K. Am J Clin Dermatol 2017 Jun;18(3):373-381. PMID 28283893
C2-7
In cultured melanocytes and keratinocyte-melanocyte models, tranexamic acid reduces melanin content, tyrosinase activity and tyrosinase protein by acting on signalling upstream of the enzyme, rather than being characterised as a direct tyrosinase-enzyme inhibitor. It does so both through a keratinocyte paracrine route (tranexamic acid raised keratinocyte TGF-beta1, which suppressed melanogenesis in melanocytes) and directly on melanocytes (ERK-MITF degradation; cAMP-PKA-CREB-MITF; VEGF-receptor signalling). The evidence is in vitro; in a 30-patient refractory-melasma series, oral tranexamic acid was followed by lower epidermal pigmentation and Melan-A staining.
VerifiedOne of 5 sources behind this claim · see the others
The record
Kim MS, Bang SH, Kim JH, Shin HJ, Choi JH, Chang SE. Ann Dermatol 2015;27(3):250-6. PMID 26082580
VerifiedOne of 5 sources behind this claim · see the others
The record
Xing X, Xu Z, Chen L, Jin S, Zhang C, Xiang L. Exp Dermatol 2021 Dec 17;31(4):633-640. PMID 34862827
VerifiedOne of 5 sources behind this claim · see the others
The record
Bae YJ, Lee EJ, Kim JY, Park S, Hwang S, Kwon IJ, Alqahtani JM, Oh SH. Exp Dermatol 2025;34(12):e70194. PMID 41392597
VerifiedOne of 5 sources behind this claim · see the others
The record
Zhu JW, Ni YJ, Tong XY, Guo X, Wu XP, Lu ZF. Int J Med Sci 2020;17(7):903-911. PMID 32308543
VerifiedOne of 5 sources behind this claim · see the others
The record
Nagaraju D, Bhattacharjee R, Vinay K, Saikia UN, Parsad D, Kumaran MS. Dermatol Ther 2018;31(5):e12704. PMID 30253023
C3-1
2-5% niacinamide produced statistically significant melanin-density reduction over 4-8 weeks (35-68% melanosome-transfer inhibition in coculture).
VerifiedOne source behind this claim
The record
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE · 2002 · The British journal of dermatology 147:20-31
C4-1
Azelaic acid 15-20% produced brightening comparable to 4% hydroquinone for melasma over 24 weeks, with better tolerability and no ochronosis or sensitization, replicated across Fitzpatrick III-V comparative studies.
VerifiedOne of 5 sources behind this claim · see the others
The record
The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream.
Baliña LM, Graupe K · 1991 · International journal of dermatology 30:893-5
VerifiedOne of 5 sources behind this claim · see the others
The record
Interventions for melasma.
Rajaratnam R, Halpern J, Salim A, Emmett C · 2010 · The Cochrane database of systematic reviews 2010:CD003583
VerifiedOne of 5 sources behind this claim · see the others
The record
Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.
Farshi S · 2011 · Journal of cosmetic dermatology 10:282-7
VerifiedOne of 5 sources behind this claim · see the others
The record
A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations.
Petrovici AG, Spennato M, Bîtcan I, Péter F, Cotarcă L, Todea A, Ordodi VL · 2025 · Pharmaceuticals (Basel, Switzerland) 18
VerifiedOne of 5 sources behind this claim · see the others
The record
Topical and Systemic Therapies in Melasma: A Systematic Review.
Sarkar R, Handog EB, Das A, Bansal A, Macarayo MJ, Keshavmurthy V, Narayan V, Jagadeesan S, Pipo E, Ibaviosa GM, Podder I, Bansal S · 2023 · Indian dermatology online journal 14:769-781
C12-3
Tranexamic acid produced significantly greater melasma improvement (MASI) than ascorbic acid mesotherapy in skin-of-color patients.
VerifiedOne source behind this claim
The record
Comparison of the Efficacy of Intralesional Ascorbic Acid Mesotherapy and Intralesional Tranexamic Acid in Treating Melasma in the Skin of Colour Population.
Aslam H, Muhammad A, Ullah A, Aziz N, Lakhiar JA, Ahmad B, Shahzadi A, Ahmad A, Chandni, Virdi G · 2025 · Cureus 17:e87851
C12-5
Niacinamide at 10-12% blocks melanosome transfer.
VerifiedOne source behind this claim
The record
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE · 2002 · The British journal of dermatology 147:20-31
C13-2
Essential oils marketed as natural (lavender, tea tree) are a documented cause of allergic contact dermatitis.
VerifiedOne of 2 sources behind this claim · see the other
The record
Art of Prevention: Essential Oils - Natural Products Not Necessarily Safe.
Sindle A, Martin K · 2021 · International journal of women's dermatology 7:304-308
VerifiedOne of 2 sources behind this claim · see the other
The record
Allergic contact dermatitis from essential oil in consumer products: Mode of uses and value of patch tests with an essential oil series. Results of a French study of the DAG (Dermato-Allergology group of the French Society of Dermatology).
Barbaud A, Kurihara F, Raison-Peyron N, Milpied B, Valois A, Assier H, Morice C, Manciet JR, Gener G, Giordano-Labadie F, Marcant P, Bernier C, Amsler E, Crepy MN, Tetart F, Soria A, le Bouëdec MF, Dermato-Allergology Group of the French Society of Dermatology (DAG) · 2023 · Contact dermatitis 89:190-197
C14-3
Essential oils (lavender, tea tree) are a documented cause of allergic contact dermatitis.
VerifiedOne of 2 sources behind this claim · see the other
The record
Art of Prevention: Essential Oils - Natural Products Not Necessarily Safe.
Sindle A, Martin K · 2021 · International journal of women's dermatology 7:304-308
VerifiedOne of 2 sources behind this claim · see the other
The record
Allergic contact dermatitis from essential oil in consumer products: Mode of uses and value of patch tests with an essential oil series. Results of a French study of the DAG (Dermato-Allergology group of the French Society of Dermatology).
Barbaud A, Kurihara F, Raison-Peyron N, Milpied B, Valois A, Assier H, Morice C, Manciet JR, Gener G, Giordano-Labadie F, Marcant P, Bernier C, Amsler E, Crepy MN, Tetart F, Soria A, le Bouëdec MF, Dermato-Allergology Group of the French Society of Dermatology (DAG) · 2023 · Contact dermatitis 89:190-197
C18-2
PIH affects darker skin with greater frequency/severity; azelaic acid, niacinamide, ascorbic acid are recognized topical depigmenting agents in skin of color.
VerifiedOne source behind this claim
The record
Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color.
Davis EC, Callender VD · 2010 · The Journal of clinical and aesthetic dermatology 3:20-31
C18-6
Commercial azelaic acid is produced almost entirely by ozonolysis of oleic acid; occurs in grains but is not extracted from them at usable scale.
VerifiedOne of 2 sources behind this claim · see the other
The record
Extraction and Quantification of Azelaic Acid from Different Wheat Samples (Triticum durum Desf.) and Evaluation of Their Antimicrobial and Antioxidant Activities.
Chiara Spaggiari, Giannamaria Annunziato, Costanza Spadini, Sabrina Lucia Montanaro, Mattia Iannarelli, Clotilde Silvia Cabassi, Gabriele Costantino · 2023 · Molecules (Basel, Switzerland) 28
VerifiedOne of 2 sources behind this claim · see the other
The record
Characterizing the Potential for Sustainable Azelaic Acid Production from High-Oleic Vegetable Oil Using Two-Step Oxidative Cleavage.
Kudli LP, Cortés-Peña YR, Bhagwat SS, Guest JS · 2026 · ACS ES T Eng 6:391-403
C19-1
Urushiol (poison ivy) causes contact dermatitis; a natural compound that is highly irritating.
Verified
C19-2
Aristolochic acid (found in several traditional-medicine plants) is nephrotoxic.
Verified
C19-3
Essential oils are among the most common contact sensitizers in cosmetic dermatology.
Verified
C19-4
Tea tree oil is genuinely antimicrobial in vitro, but efficacy is concentration-dependent and the same concentration that works often irritates; potency varies batch to batch as a botanical extract.
Verified
C21-3
Retinoid efficacy for photoaging is dose-dependent; irritation is concentration-dependent.
VerifiedOne source behind this claim
The record
Topical Treatments for Photoaged Skin.
Sadick N, Pannu S, Abidi Z, Arruda S · 2023 · Journal of drugs in dermatology : JDD 22:867-873
C21-7
Topical retinoids reduce hyperpigmentation in patients with skin of color and should be started early.
VerifiedOne source behind this claim
The record
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E · 2022 · American journal of clinical dermatology 23:69-81
C21-8
All-Black-patient RCT: 0.1% tretinoin improved melasma (MASI) 32% vs 10% vehicle over 40 weeks; side effects limited to mild retinoid dermatitis in 67%.
VerifiedOne source behind this claim
The record
Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial.
Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ · 1994 · Archives of dermatology 130:727-33
C22-3
Topical retinoids build collagen; on skin of color the gentlest effective strength avoids irritation-triggered PIH.
VerifiedOne of 4 sources behind this claim · see the others
The record
Topical Treatments for Photoaged Skin.
Sadick N, Pannu S, Abidi Z, Arruda S · 2023 · Journal of drugs in dermatology : JDD 22:867-873
VerifiedOne of 4 sources behind this claim · see the others
The record
Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials.
Sitohang IBS, Makes WI, Sandora N, Suryanegara J · 2022 · International journal of women's dermatology 8:e003
VerifiedOne of 4 sources behind this claim · see the others
The record
Acne in ethnic skin: special considerations for therapy.
Callender VD · 2004 · Dermatologic therapy 17:184-95
VerifiedOne of 4 sources behind this claim · see the others
The record
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E · 2022 · American journal of clinical dermatology 23:69-81
C24-3
Topical retinoids and azelaic acid treat acne and reduce post-acne hyperpigmentation in skin of color.
VerifiedOne of 2 sources behind this claim · see the other
The record
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E · 2022 · American journal of clinical dermatology 23:69-81
VerifiedOne of 2 sources behind this claim · see the other
The record
Dermatology: how to manage acne in skin of colour.
Chiang C, Ward M, Gooderham M · 2022 · Drugs in context 11
C28-2
Evidence-based skin repair rests on gentle pH-balanced cleansing, ceramide- or urea-based moisturizers, and photoprotection.
VerifiedOne source behind this claim
The record
Kaminsky et al. 2026, DOI 10.1093/oncolo/oyag194
C29-3
Ceramide subclass composition is tightly linked to barrier function; a skewed or altered ceramide profile correlates with barrier dysfunction.
VerifiedOne source behind this claim
The record
Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition
Jannik Rousel, Andreea Nădăban, Mahdi Saghari, Lisa Pagan, Ahnjili Zhuparris, Bart Theelen, Tom Gambrah, Hein E. C. van der Wall, Rob J. Vreeken, Gary L. Feiss, Tessa Niemeyer‐van der Kolk, Jacobus Burggraaf, Martijn B. A. van Doorn, Joke A. Bouwstra, Robert Rissmann · 2024 · Experimental Dermatology 33
C35-12
Azelaic acid is first-line topical alongside retinoids and BP.
VerifiedOne source behind this claim
The record
Eichenfield et al. 2021, PMID 34812859
CAMIST-4
Anua's Niacinamide Tranexamic Acid Brightening Booster Toner discloses tranexamic acid at 1,000ppm (0.1%), below every published topical tranexamic acid RCT concentration identified (2-10% range) and below the Ingredient Canon's 2-5% effective-concentration threshold. Niacinamide in the same product is disclosed at 5%, within Canon range.
Verified
CAMIST-8
No published topical tranexamic acid RCT tests a concentration below 2%; identified trials and reviews cluster at 2-10%, with most positive melasma outcomes reported at 3-5%. A 0.1% commercial toner concentration sits below the floor of tested literature -- this is untested territory, not a concentration shown ineffective.
Verified
CCAST-1
No controlled clinical trial was located in which castor oil regrew eyelashes, eyebrows or scalp hair, and eyelash-serum evidence reviews grade castor oil at the lowest evidence tier (Grade D, reflecting absence of adequate evidence, not disproof by trial). The only related trial found was in blepharitis (twice-daily castor oil reduced dry-eye symptom scores and eyelid margin thickening over four weeks) and did not measure lash growth. There is no evidence that castor oil increases anagen-phase hair count or follicle activity in humans; the perceived effect is most likely shine and reduced breakage.
Verified
CCOCOA-1
Cocoa butter does not prevent or fade stretch marks: a randomized controlled trial of cocoa butter for striae found stretch marks in 45% of the cocoa butter group versus 49% of the comparison group (PMID 18715434), and reviews of topical stretch-mark prevention report no effect for cocoa butter (PMIDs 26486318, 25255817, 23313995).
VerifiedOne of 4 sources behind this claim · see the others
The record
Osman H, Usta IM, Rubeiz N, Abu-Rustum R, Charara I, Nassar AH. BJOG 2008 Aug;115(9):1138-42. PMID 18715434
VerifiedOne of 4 sources behind this claim · see the others
The record
Ud-Din S, McGeorge D, Bayat A. J Eur Acad Dermatol Venereol 2015 Oct;30(2):211-22. PMID 26486318
VerifiedOne of 4 sources behind this claim · see the others
The record
Korgavkar K, Wang F. Br J Dermatol 2015 Feb;172(3):606-15. PMID 25255817
VerifiedOne of 4 sources behind this claim · see the others
The record
Moore J, Kelsberg G, Safranek S. J Fam Pract 2012 Dec;61(12):757-8. PMID 23313995
CHFN-25
Tea tree oil (Melaleuca alternifolia) demonstrates real antibacterial activity against Staphylococcus aureus and related skin bacteria, incl. in a hand-hygiene RCT.
Verified
CKOJIC-1
Kojic acid is a PubMed-studied topical melasma treatment among 35 RCT agents reviewed in a 2019 systematic review, but sits in the "more research needed on optimal concentration/formulation" evidence tier rather than the "strong clinical recommendation" tier earned by cysteamine, triple combination therapy, and tranexamic acid.
Verified
CNAT-OAT-1
Colloidal oatmeal (finely milled, formulated) is an FDA-recognised OTC skin protectant: a randomised investigator-blinded trial of a 1% colloidal oat eczema cream reduced EASI and ADSI by 51% and 54% at 14 days with improved skin pH, barrier function and microbiome diversity versus a standard moisturiser; colloidal oat extracts upregulate epidermal-differentiation, tight-junction and lipid genes and improved dryness and barrier function in a 50-subject blinded study. Evidence is for colloidal products, not raw kitchen oats; it is a barrier/itch ingredient, not a pigment one; no skin-of-color-specific trial.
VerifiedOne of 2 sources behind this claim · see the other
The record
Capone K, Kirchner F, Klein SL, Tierney NK. J Drugs Dermatol 2020 May;19(5):524-531. PMID 32484623
VerifiedOne of 2 sources behind this claim · see the other
The record
Ilnytska O, Kaur S, Chon S, Reynertson KA, Nebus J, Garay M, Mahmood K, Southall MD. J Drugs Dermatol 2016 Jun;15(6):684-90. PMID 27272074
CPEEL-14
Systematic review of 48 studies (1,356 skin-of-colour PIH patients; 20% FST III, 40% IV, 34% V, 6% VI; 70% Black): topical retinoids most used (22%) with partial improvement in 85%; laser (17%) partial improvement 66% and the only intervention with complete resolution in a subgroup (26%) but with reported PIH exacerbation; chemical peels (9%) and hydroquinone (7%) among treatments with less effective outcomes; overall lack of robust efficacy across modalities.
Verified
CRICE-4
Kojic acid is a secondary metabolite primarily synthesized by Aspergillus oryzae (PMID 41084052) and is described as primarily a fermentation metabolite of A. oryzae (PMID 42727430); a fungal isolate from rice husk accumulated 8.63 to 12.87 g/L of kojic acid over 12 days of static fermentation (PMID 35928501; the species is not named in the retrieved abstract). No PubMed study was located that measures the kojic acid content of home-prepared rice water (PubMed 'kojic acid rice water', run 2026-09-30, 1 result, PMID 37799972, a black soldier fly larvae oil study that does not measure rice water), so a statement that home rice water contains kojic acid has no source located.
Verified
CSHEA-1
Shea butter is a barrier-supporting occlusive (mostly oleic ~40-55% and stearic ~35-45% fatty acids) with a triterpene-rich unsaponifiable fraction that has anti-inflammatory activity; it is a component of evidence-backed eczema barrier formulations, with traditional wound-healing use. Comedogenicity low.
VerifiedOne of 3 sources behind this claim · see the others
The record
Akihisa T, Kojima N, Kikuchi T, Yasukawa K, Tokuda H, T Masters E, Manosroi A, Manosroi J. J Oleo Sci 2010;59(6):273-80. PMID 20484832
VerifiedOne of 3 sources behind this claim · see the others
The record
Micali G, Paternò V, Cannarella R, Dinotta F, Lacarrubba F. G Ital Dermatol Venereol 2018 Jan;153(3):396-402. PMID 29368843
VerifiedOne of 3 sources behind this claim · see the others
The record
Anyanwu EG, Onuchukwu CL, Ojukwu CP, Anyanwu CN. J Ethnopharmacol 2026 Jan;361:121293. PMID 41619863
CSHEA-2
No study located shows shea BUTTER fades hyperpigmentation: the published melanogenesis-inhibition result is for a lab extract of the defatted kernel, not the butter; the Library declines the "shea fades dark spots" claim.
VerifiedOne source behind this claim
The record
Zhang J, Kurita M, Shinozaki T, Ukiya M, Yasukawa K, Shimizu N, Tokuda H, Masters ET, Akihisa M, Akihisa T. Phytochemistry 2014 Oct;108:157-70. PMID 25446237
CTHIA-7
Systematic review of topical PIH treatments (47 studies, 1,853 subjects, GRADE-assessed): thiamidol among the topical agents supported by high-quality studies, alongside retinoids, hydroxy acids, corticosteroids, niacinamide.
Verified
RNAT-1
Whether an ingredient is natural or synthetic does not predict its safety or efficacy; judge any ingredient by mechanism, concentration, evidence base and consistency of the source material.
SYNTHESIZED
Synthesized from:
  • C19-1 Urushiol (poison ivy) causes contact dermatitis; a natural compound that is highly irritating.
  • C19-2 Aristolochic acid (found in several traditional-medicine plants) is nephrotoxic.
  • C19-3 Essential oils are among the most common contact sensitizers in cosmetic dermatology.
  • C19-4 Tea tree oil is genuinely antimicrobial in vitro, but efficacy is concentration-dependent and the same concentration that works often irritates; potency varies batch to batch as a botanical extract.
  • C13-2 Essential oils marketed as natural (lavender, tea tree) are a documented cause of allergic contact dermatitis. PMID 34222588 PMC8243157 DOI PMID 37403438 DOI
  • CAMIST-4 Anua's Niacinamide Tranexamic Acid Brightening Booster Toner discloses tranexamic acid at 1,000ppm (0.1%), below every published topical tranexamic acid RCT concentration identified (2-10% range) and below the Ingredient Canon's 2-5% effective-concentration threshold. Niacinamide in the same product is disclosed at 5%, within Canon range.
  • CAMIST-8 No published topical tranexamic acid RCT tests a concentration below 2%; identified trials and reviews cluster at 2-10%, with most positive melasma outcomes reported at 3-5%. A 0.1% commercial toner concentration sits below the floor of tested literature -- this is untested territory, not a concentration shown ineffective.
RNAT-2
For PIH on Fitzpatrick IV-VI skin, treat natural oils and butters as seal/barrier support layered over clinically evidenced actives, not as the primary intervention.
SYNTHESIZED
Synthesized from:
  • CSHEA-2 No study located shows shea BUTTER fades hyperpigmentation: the published melanogenesis-inhibition result is for a lab extract of the defatted kernel, not the butter; the Library declines the "shea fades dark spots" claim. PMID 25446237
  • C18-2 PIH affects darker skin with greater frequency/severity; azelaic acid, niacinamide, ascorbic acid are recognized topical depigmenting agents in skin of color. PMID 20725554 PMC2921758
  • C24-3 Topical retinoids and azelaic acid treat acne and reduce post-acne hyperpigmentation in skin of color. PMID 34751927 PMC8776661 DOI PMID 35720053 PMC9165627 DOI
  • C21-7 Topical retinoids reduce hyperpigmentation in patients with skin of color and should be started early. PMID 34751927 PMC8776661 DOI
  • CTHIA-7 Systematic review of topical PIH treatments (47 studies, 1,853 subjects, GRADE-assessed): thiamidol among the topical agents supported by high-quality studies, alongside retinoids, hydroxy acids, corticosteroids, niacinamide.
  • C9-4 Topical vitamin E does not improve scar appearance (no effect or worsened in 90% of a split-scar trial) and causes contact dermatitis in ~33% of users. PMID 10417589 DOI PMID 26977069 DOI